Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
Article
Google Scholar
Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C et al (2016) Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2:16012. https://doi.org/10.1038/npjbcancer.2016.12
Article
Google Scholar
Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour heterogeneity in the clinic. Nature 501:355–364
Article
CAS
Google Scholar
Wang S, Wang Z, Li R, You C, Mao N, Jiang T et al (2022) Association between quantitative and qualitative image features of contrast-enhanced mammography and molecular subtypes of breast cancer. Quant Imaging Med Surg 12:1270–1280
Article
CAS
Google Scholar
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697–5704
Article
CAS
Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
Article
CAS
Google Scholar
Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J et al (2014) Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 106:dju152. https://doi.org/10.1093/jnci/dju152
Article
CAS
Google Scholar
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32
Article
Google Scholar
Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y et al (2014) Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat 145:615–623
Article
CAS
Google Scholar
Vaz-Luis I, Winer EP, Lin NU (2013) Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 24:283–291
Article
CAS
Google Scholar
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS et al (2012) Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the national comprehensive cancer network: a prospective cohort study. Breast Cancer Res 14:R129. https://doi.org/10.1186/bcr3324
Article
CAS
Google Scholar
Elias SG, Adams A, Wisner DJ, Esserman LJ, van’t Veer LJ, Mali WP et al (2014) Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23:1464–1483
Article
CAS
Google Scholar
Agrawal G, Chen JH, Baek HM, Hsiang D, Mehta RS, Nalcioglu O et al (2007) MRI features of breast cancer: a correlation study with HER-2 receptor. Ann Oncol 18:1903–1904
Article
CAS
Google Scholar
Seo BK, Pisano ED, Kuzimak CM, Koomen M, Pavic D, Lee Y et al (2006) Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 13:1211–1218
Article
Google Scholar
Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S et al (2008) Estrogen Receptor-Negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 246:367–375
Article
Google Scholar
Jochelson MS, Lobbes MBI (2021) Contrast-enhanced mammography: state of the art. Radiology 299:36–48
Article
Google Scholar
Lalji UC, Jeukens CR, Houben I, Nelemans PJ, van Engen RE, van Wylick E et al (2015) Evaluation of low-energy contrast-enhanced spectral mammography images by comparing them to full-field digital mammography using EUREF image quality criteria. Eur Radiol 25:2813–2820
Article
CAS
Google Scholar
Lewin J (2018) Comparison of contrast-enhanced mammography and contrast-enhanced breast MR imaging. Magn Reason Imaging Clin N Am 26:259–263
Article
Google Scholar
Li L, Roth R, Germaine P, Ren S, Lee M, Hunter K et al (2017) Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): a retrospective comparison in 66 breast lesions. Diagn Interv Imaging 98:113–123
Article
CAS
Google Scholar
Fallenberg EM, Schmitzberger FF, Amer H, Ingold-Heppner B, Balleyguier C, Diekmann F et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI—clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764
Article
Google Scholar
Xing D, Lv Y, Sun B, Xie H, Dong J, Hao C et al (2019) Diagnostic value of contrast-enhanced spectral mammography in comparison to magnetic resonance imaging in breast lesions. J Comput Assist Tomogr 43:245–251
Article
Google Scholar
Kim JY, Kim SH, Kim YJ, Kang BJ, An YY, Lee AW et al (2014) Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging 33:72–80
Article
Google Scholar
Yamaguchi K, Abe H, Newstead GM, Egashira R, Nakazono T, Imaizumi T et al (2014) Intratumoral heterogeneity of the distribution of kinetic parameters in breast cancer: comparison based on the molecular subtypes of invasive breast cancer. Breast Cancer 22:496–502
Article
Google Scholar
Blaschke E, Abe H (2015) MRI phenotype of breast cancer: kinetic assessment for molecular subtypes. J Magn Reson imaging 42:920–924
Article
Google Scholar
Barra FR, Sobrinho AB, Barra RR, Magalhães MT, Aguiar LR, de Albuquerque GFL et al (2018) Contrast-enhanced mammography (CEM) for detecting residual disease after neoadjuvant chemotherapy: a comparison with breast magnetic resonance imaging (MRI). Biomed Res Int 2018:1–9
Article
Google Scholar
Mohamed Kamal R, Hussien Helal M, Wessam R, Mahmoud Mansour S, Godda I, Alieldin N (2015) Contrast-enhanced spectral mammography: impact of the qualitative morphology descriptors on the diagnosis of breast lesions. Eur J Radiol 84:1049–1055
Article
Google Scholar
Lv Y, Chi X, Sun B, Lin S, Xing D (2020) Diagnostic value of quantitative gray-scale analysis of contrast-enhanced spectral mammography for benign and malignant breast lesions. J Comput Assist Tomogr 44:405–412
Article
Google Scholar
Rudnicki W, Heinze S, Popiela T, Kojs Z, Luczynska E (2020) Quantitative assessment of contrast enhancement on contrast enhancement spectral mammography (CESM) and comparison with qualitative assessment. Anticancer Res 40:2925–2932
Article
CAS
Google Scholar
Rudnicki W, Heinze S, Niemiec J, Kojs Z, Sas-Korczynska B, Hendrick E et al (2019) Correlation between quantitative assessment of contrast enhancement in contrast-enhanced spectral mammography (CESM) and histopathology-preliminary results. Eur Radiol 29:6220–6226
Article
Google Scholar
Sickles EA, D’Orsi CJ, Bassett LW (2013) ACR BI-RADS mammography. In: ACR BI-RADS Atlas, breast imaging reporting and data system, 5th Edition, American College of Radiology, Reston
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747
Article
CAS
Google Scholar
Savaridas SL, Tennant SL (2022) Quantifying lesion enhancement on contrast-enhanced mammography: a review of published data. Clin Radiol 77:e313–e320
Article
CAS
Google Scholar
Łuczyńska E, Heinze-Paluchowska S, Hendrick E, Dyczek S, Ryś J, Herman K et al (2015) Comparison between breast MRI and contrast-enhanced spectral mammography. Med Sci Monit 21:1358–1367
Article
Google Scholar
Song SE, Bae MS, Chang JM, Cho N, Ryu HS, Moon WK (2017) MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiol 58:792–799
Article
Google Scholar
Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35
Article
CAS
Google Scholar
Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE (2017) BI-RADS® fifth edition: a summary of changes. Diagn Interv Imaging 98:179–190
Article
CAS
Google Scholar
Chi X, Zhang L, Xing D, Gong P, Chen Q, Lv Y (2020) Diagnostic value of the enhancement intensity and enhancement pattern of CESM to benign and malignant breast lesions. Medicine (Baltim) 99:e22097. https://doi.org/10.1097/MD.0000000000022097
Article
Google Scholar
Travieso-Aja MM, Maldonado-Saluzzi D, Naranjo-Santana P, Fernández-Ruiz C, Severino-Rondón W, Rodríguez Rodríguez M et al (2019) Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography. Radiologia 61:477–488
Article
CAS
Google Scholar
Wilhelm A, McDonough MD, DePeri ER (2012) Malignancy rates of non-masslike enhancement on breast magnetic resonance imaging using American College of Radiology Breast Imaging Reporting and Data System descriptors. Breast J 18:523–526
Article
Google Scholar
Kawashima H, Inokuchi M, Furukawa H, Ikeda H, Kitamura S (2014) Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus 3:240. https://doi.org/10.1186/2193-1801-3-240
Article
Google Scholar
Costantini M, Belli P, Distefano D, Bufi E, Matteo MD, Rinaldi P et al (2012) Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors. Clin Breast Cancer 12:331–339
Article
Google Scholar